Revier Therapeutics
PrivateLast Round
Seed
Aug 25, 2026
Total Funding Raised
$7M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Revier Therapeutics operates in Healthcare & Life Sciences and is based in Heidelberg. Its latest recorded funding round was a Seed round in August 2026.
Revier Therapeutics is a biotechnology company developing disease-modifying small molecule therapies that selectively target class IIa HDACs to treat cardiometabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Revier Therapeutics Comparables
Compare Revier Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Brano Therapeutics | 83% | |
| Tenaya Therapeutics | 71% | |
| Fauna Bio | 70% |
For institutional investors. Book with your work email.
Revier Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Revier Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KHAN Technology Transfer Fund II | Seed |
| VORNvc | Seed |
| High-Tech Gründerfonds | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 25, 2026
$7M round led by KHAN Technology Transfer Fund II.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 26, 2026
Revier Therapeutics GmbH is working on a therapeutic approach to atherosclerotic cardiovascular disease (ASCVD) as its second preclinical program.
- is_developingAug 25, 2026
Revier Therapeutics GmbH launches with €6 million in seed funding and aims to develop novel therapies for cardiometabolic diseases through selective inhibition of Class IIa histone deacetylases, using the capital to advance its preclinical pipeline and build scientific, clinical, and operational structures in Germany on Aug 26th '26.
- receives_financingAug 25, 2026
On Aug 28th '26, Revier Therapeutics GmbH receives $7M Seed financing led by the KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds, VORNvc, and private investors through Revier Invest Heidelberg, to develop cardiometabolic therapies in Germany.
For institutional investors. Book with your work email.
Revier Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Revier Therapeutics's valuation, stock price, and market status.
Is Revier Therapeutics a public or private company?
Revier Therapeutics is a private company.
What is the current stock price of Revier Therapeutics?
Revier Therapeutics is a private company, so its shares have no public market price. Caplight tracks Revier Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Revier Therapeutics worth (valuation)?
Valuation information for Revier Therapeutics is not publicly available.
Can I buy Revier Therapeutics stock?
Revier Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Revier Therapeutics's last funding round?
Revier Therapeutics's most recent funding round was Seed on August 25, 2026.
Who are the main investors in Revier Therapeutics?
Key investors in Revier Therapeutics include KHAN Technology Transfer Fund II.
Will Revier Therapeutics IPO soon?
No public IPO plans have been announced for Revier Therapeutics.
How can I track Revier Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Revier Therapeutics's shares on secondary markets.